For example, LD IL-2 therapy ranging from 1.0x106 IU/day (276), 1.5x106 IU/day (277), or 1.0x106 IU every other day (278) led to 2-5 fold expansion of Tregs over baseline in HCV-induced vasculitis (277), chronic GVHD (275, 276), and SLE (278, 279) patients, which appeared to correlate with disease improvement in a subset of patients. Here, IL2 is linked to systemic lupus erythematosus.